HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 2007-0204v1 25/10/2575    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Dennis, J. E. Articles by Goltry, K. L. Search for Related Content PubMed PubMed Citation Articles by Dennis, J. E. Articles by Goltry, K. L.

TECHNOLOGY DEVELOPMENT

Clinical-Scale Expansion of a Mixed Population of Bone Marrow-Derived Stem and Progenitor Cells for Potential Use in Bone Tissue Regeneration

^aDepartment of Orthopaedics, Case Western Reserve University, Cleveland, Ohio, USA;
^bAastrom Biosciences Inc., Ann Arbor, Michigan, USA

Key Words. Bone marrow • Osteogenesis • Bioreactor • Ex vivo expansion

Correspondence: James E. Dennis, Ph.D., Department of Orthopaedics, University Hospitals of Cleveland, 6^th Floor Hanna Building, 11100 Cedar Avenue, Cleveland, Ohio 44106, USA. Telephone: (216) 368-3567; Fax: (216) 368-1332; e-mail: James.Dennis{at}case.edu

Received March 26, 2007; accepted for publication May 25, 2007.
First published online in STEM CELLS EXPRESS   June 21, 2007.



Preclinical and clinical studies have demonstrated the ability of bone marrow derived stem and progenitor cells to regenerate many tissues, including bone. Methods to expand or enrich progenitors from bone marrow are common; however, these methods include many steps not amenable to clinical use. A closed automated cell production culture system was developed for clinical-scale ex vivo production of bone marrow-derived stem and progenitor cells for hematopoietic reconstitution. The current study tested the ability of this bioreactor system to produce progenitor cells, termed tissue repair cells (TRC), possessing osteogenic potential. Three TRC formulations were evaluated: (a) cells cultured without exogenous cytokines (TRC); (b) cells cultured with exogenous cytokines (TRC-C); and (c) an adherent subset of TRC-C (TRC-C^Ad). Starting human bone marrow mononuclear cells (BM MNC) and TRC products were characterized for the expression of cell surface markers, in vitro colony forming ability, and in vivo osteogenic potential. Results showed significant expansion of mesenchymal progenitors (CD90+, CD105+, and CD166+) in each TRC formulation. In vivo bone formation, measured by histology, was highest in the TRC group, followed by TRC-C^Ad and TRC-C. The TRC product outperformed starting BM MNC and had equivalent bone forming potential to purified MSCs at the same cell dose. Post hoc analysis revealed that the presence of CD90+, CD105+, and CD166+ correlated strongly with in vivo bone formation scores (r² > .95). These results demonstrate that this bioreactor system can be used to generate, in a single step, a population of progenitor cells with potent osteogenic potential.

Disclosure of potential conflicts of interest is found at the end of this article.